Safety of placebo controls in pediatric hypertension trials

Hypertension

Volumn 51, Issue 4, 2008, Pages 829-833

  Smith, P Brian ^a,b   Li, Jennifer S ^a,b   Murphy, M Dianne ^a   Califf, Robert M ^b   Benjamin Jr , Daniel K ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Adverse events; Hypertension; Medical ethics; Pediatric drug therapy; Placebo controlled clinical trials

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; ENALAPRIL; FELODIPINE; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; QUINAPRIL; RAMIPRIL;

AGITATION; ARTICLE; ASTHMA; BLOOD DISEASE; BLURRED VISION; BREAST DISEASE; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSPNEA; EAR DISEASE; EYE DISEASE; FALLING; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; LIVER FUNCTION TEST; LYMPHATIC SYSTEM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PYURIA; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RISK; SEIZURE; SIDE EFFECT; SKIN DISEASE; SYNCOPE; TACHYCARDIA; THORAX PAIN; TREMOR; URINARY TRACT DISEASE; VASCULAR DISEASE; VOMITING; ADOLESCENT; CHILD; CONTROLLED CLINICAL TRIAL; ETHICS; FACTUAL DATABASE; MEDICAL ETHICS; META ANALYSIS; SAFETY; STANDARD; STATISTICS;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; ETHICS, MEDICAL; HUMANS; HYPERTENSION; PLACEBOS; SAFETY;

EID: 42049100377     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.104950     Document Type: Article

References (19)

1. Food and Drug Administration Modernization Act of 1997. 111 Stat 2296. Vol 105. 105th Congress ed;1997:107-109.
2. Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA. 2006;296:1266-1273.
3. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK Jr. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297:480-488.
4. Food and Drug Administration Web site. Pediatric exclusivity labeling changes. Available at: http://www.fda.gov/cder/pediatric/labelchange.htm. Accessed December 22, 2007.
5. Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart J. 2002;144:608-614.
6. Vitiello B, Jensen PS. Medication development and testing in children and adolescents. Current problems, future1 directions. Arch Gen Psychiatry. 1997;54:871-876.
7. Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95:286-294.
8. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394-398.
9. Al-Khatib SM, Califf RM, Hasselblad V, Alexander JH, McCrory DC, Sugarman J. Medicine. Placebo-controls in short-term clinical trials of hypertension. Science. 2001;292:2013-2015.
10. Flynn JT. Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies. Hypertension. 2003;42:865-869.
11. Declaration of Helsinki VI: Ethical Principles for Medical Research Involving Human Subjects. Presented at the 52nd World Medical Assembly; October 3-7, 2000; Edinburgh, Scotland.
12. Note of Clarification on Paragraph 29. Presented at the World Medical Association General Assembly; October 3-7, 2002; Washington, DC.
13. Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003;17:188-204.
14. Groupe CA. Final summary minutes - Cardiovascular and Drugs Advisory Committee Meeting. In: Research FaDA-CfDEa. Gaithersburg, MD; 2006.
15. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med. 2000;160:1449-1454.
16. Sorof JM, Urbina EM, Cunningham RJ, Hogg RJ, Moxey-Mims M, Eissa MA, Rolf C; Ziac Pediatric Hypertension Study Group. Screening for eligibility in the study of antihypertensive medication in children: experience from the Ziac Pediatric Hypertension Study. Am J Hypertens. 2001;14:783-787.
17. Flynn JT. Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol. 2001;12:177-188.
18. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
19. Kay JD, Sinaiko AR, Daniels SR. Pediatric hypertension. Am Heart J. 2001;142:422-432.